Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.30 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | PPARA | Q07869 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26431999 | 0.74 | TSHR (0.40) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL3378298 | 0.72 | TSHR (0.38) | TSHRALDH1A1CYP2D6CYP2C19HIF1A | |
| SCHEMBL85493 | 0.71 | TSHR (0.57) | TSHRALDH1A1TP53CYP2D6CYP2C19 | |
| SCHEMBL11675279 | 0.71 | — | — | |
| Ammonia Solution, Strong SCHEMBL28635066 | 0.68 | TSHR (0.53) | TSHRALDH1A1TP53CYP2D6CYP2C19 | |
| Ammonia Solution, Strong SCHEMBL28635068 | 0.68 | TSHR (0.53) | TSHRALDH1A1TP53CYP2D6CYP2C19 | |
| SCHEMBL28528092 | 0.67 | TSHR (0.47) | TSHRALDH1A1TP53CYP2D6CYP2C19 | |
| SCHEMBL14573217 | 0.65 | TSHR (0.50) | TSHRALDH1A1TP53CYP2D6CYP2C19 | |
| SCHEMBL301639 | 0.65 | TSHR (0.50) | TSHRALDH1A1TP53CYP2D6CYP2C19 | |
| SCHEMBL10897817 | 0.65 | THRB (0.43) | TSHRALDH1A1TP53CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140227201-A1 | Antimicrobial Gel Formulations | NOVABAY PHARMACEUTICALS, INC. | 2014-08-14 | — | — | US | claimed |
| US-20120282351-A1 | System and Method for The Prevention of Bacterial and Fungal Infections Including Urinary Tract Infections (UTI) Using N-Halogenated Amino Acids | NOVABAY PHARMACEUTICALS, INC. | 2012-11-08 | — | — | US | claimed |
| JP-2012500209-A | — | — | 2012-01-05 | — | — | JP | claimed |
| CN-102176818-A | Antimicrobial gel formulations | NOVABAY PHARMACEUTICALS INC | 2011-09-07 | — | — | CN | claimed |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | NOVABAY PHARMACEUTICALS, INC. | 2011-06-23 | — | — | US | claimed |
| EP-2312939-A1 | ANTIMICROBIAL GEL FORMULATIONS | NovaBay Pharmaceuticals, Inc. (US) | 2011-04-27 | — | — | EP | claimed |
| EP-2265267-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NovaBay Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| US-20100272783-A1 | Methods of Treating Infections of the Nail | NOVABAY PHARMACEUTICALS, INC. | 2010-10-28 | — | — | US | claimed |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. | 2010-03-25 | — | — | US | claimed |
| WO-2010019723-A1 | ANTIMICROBIAL GEL FORMULATIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | WO | claimed |
| WO-2010017405-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF PAIN | HELLER ADAM (US) | 2010-02-11 | — | — | WO | claimed |
| WO-2009126912-A1 | COMPOSITIONS COMPRISING N-HALOGENATED OR N, N-DIHALOGENATED AMINE FOR TREATMENT AND PROPHYLAXIS OF BRONCHOPULMONARY INFECTIONS | NOVABAY PHARMACEUTICALS, INC. (US) | 2009-10-15 | — | — | WO | claimed |
| JP-2009511493-A | — | — | 2009-03-19 | — | — | JP | claimed |
| EP-1948154-A1 | SYSTEM AND METHOD FOR THE PREVENTION OF BACTERIAL AND FUNGAL INFECTIONS INCLUDING URINARY TRACT INFECTIONS (UTI) USING N-HALOGENATED AMINO ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-07-30 | — | — | EP | claimed |
| EP-1896001-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | Novabay Pharmaceuticals, Inc. (US) | 2008-03-12 | — | — | EP | claimed |
| CN-101132785-A | N-halogenated amino acids and N, N-dihalogenated amino acids in combination with hypohalous acids | NOVABAY PHARMACEUTICALS INC (US) | 2008-02-27 | — | — | CN | claimed |
| US-20070244449-A1 | System and method for the prevention of bacterial and fungal infections including Urinary Tract Infections (UTI) using N-halogenated amino acids | NOVACAL PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | claimed |
| WO-2007044559-A1 | SYSTEM AND METHOD FOR THE PREVENTION OF BACTERIAL AND FUNGAL INFECTIONS INCLUDING URINARY TRACT INFECTIONS (UTI) USING N-HALOGENATED AMINO ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2007-04-19 | — | — | WO | claimed |
| CN-1902158-A | N,N-dihalogenated amino acids and derivatives | NOVACAL PHARMACEUTICALS INC (US) | 2007-01-24 | — | — | CN | claimed |
| WO-2006081392-A1 | N-HALOGENATED AMINO ACIDS AND N, N-DIHALOGENATED AMINO ACIDS IN COMBINATION WITH HYPOHALOUS ACIDS | NOVABAY PHARMACEUTICALS, INC. (US) | 2006-08-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100272783-A1 | Methods of Treating Infections of the Nail | POLR1C, TYR, NACA | TSHR 2015/4885ALDH1A1 1683/4885TP53 1117/4885 |
| US-20140227201-A1 | Antimicrobial Gel Formulations | CUTA, TUBA3C, POLR1C | TSHR 4545/4885ALDH1A1 1488/4885TP53 1647/4885 |
| US-20110151025-A1 | Compositions Comprising N-Halogenated or N,N-Dihalogenated Amine for Treatment and Prophylaxis of Bronchopulmonary Infections | CFTR, NAT1, ELANE | TSHR 1500/4885ALDH1A1 1852/4885TP53 3000/4885 |
| US-20100076089-A1 | ANTIMICROBIAL GEL FORMULATIONS | CUTA, TUBA3C, POLR1C | TSHR 4545/4885ALDH1A1 1488/4885TP53 1647/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.